Year One (2015-2016)

• Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration (ersjournals.com)

Year Two (2016-2017)

• Patient participation in ERS guidelines and research projects: the EMBARC experience

Year Three (2017-2018)

• Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network
• The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) ERS Clinical Research Collaboration
• The EMBARC European Bronchiectasis Registry: protocol for an international observational study
• Use of Calgary and microfluidic BioFlux systems to test the activity of fosfomycin and tobramycin alone and in combination against cystic fibrosis Pseudomonas aeruginosa biofilms

• Chest Physiotherapy in patients with Bronchiectasis – what is the current practice in Europe? | European Respiratory Society (ersjournals.com)

• Susceptibility testing and detection of β-lactam resistance mechanisms in Enterobacteriaceae: a multicentre national proficiency study - ScienceDirect

Year Four (2018-2019)

• Antimicrobial susceptibility of non-fermenting Gram-negative pathogens isolated from cystic fibrosis patients.
• Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry
• Draft Genome Sequence of Haemophilus haemolyticus Strain 16/010 O, Isolated from a Sputum Sample from a Cystic Fibrosis Patient
• Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1)
• The heterogeneity of bronchiectasis patient characteristics, management and outcomes across Europe: Data from the EMBARC registry
• A randomised placebo-controlled dose finding study of tobramycin inhalation powder (TIP) in patients with bronchiectasis (BE) and pulmonary P. aeruginosa Pa) infection (iBEST-1) | European Respiratory Society (ersjournals.com)
• Primary ciliary dyskinesia in adults with bronchiectasis: Data from the Embarc registry | European Respiratory Society (ersjournals.com)
• Characteristics of patients with pulmonary non-tuberculous Mycobacterial infection in bronchiectasis: Data from the EMBARC registry | European Respiratory Society (ersjournals.com)
• Impact of Inflammatory bowel disease in bronchiectasis (IBD-BR) data from the EMBARC registry | European Respiratory Society (ersjournals.com)

• Validity of COPD diagnosis in Bronchiectasis patients: data from the EMBARC registry | European Respiratory Society (ersjournals.com)

• New isolation of non-tuberculous mycobacteria in patients with bronchiectasis - data from the European Bronchiectasis Registry (EMBARC) | European Respiratory Society (ersjournals.com)

• PRS64 CONTENT VALIDATION OF THE RESPIRATORY SYMPTOMS SUBSCALE (RSS) OF THE QUALITY OF LIFE QUESTIONNAIRE-BRONCHIECTASIS (QOL-B) IN NON-CYSTIC FIBROSIS BRONCHIECTASIS (NON-CF BE) - Value in Health (valueinhealthjournal.com)

• Novel quantitative bronchiectasis scoring technique for chest computed tomography: BEST-CT. A study within the iABC project | European Respiratory Society (ersjournals.com)

• Hypermucoviscous Klebsiella pneumoniae: A challenge in community acquired infection - ScienceDirect

Year Five (2019-2020)

• A systematic review of pharmacotherapeutic clinical trial end-points for bronchiectasis in adults
• Draft Genome Sequence of a Haemophilus parainfluenzae Strain Isolated from a Patient with Chronic Obstructive Pulmonary Disease
• Draft genome sequence of the strain 16-537536, isolated from a patient with bronchiectasis and its relationship to the Pseudomonas koreensis group of the Pseudomonas fuorescens complex
• Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis: a post hoc analysis of the AIR-BX studies
• Multiple breath washout in bronchiectasis clinical trials: is it feasible?
• Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics

• The radiological diagnosis of bronchiectasis: what's in a name? (ersjournals.com)

• Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS | Journal of Antimicrobial Chemotherapy | Oxford Academic (oup.com)

• WGS characterization of MDR Enterobacterales with different ceftolozane/tazobactam susceptibility profiles during the SUPERIOR surveillance study in Spain | JAC-Antimicrobal Resistance | Oxford Academic (oup.com)

• Whole-genome analysis of Pandoraea species strains from cystic fibrosis patients | Future Microbiology (futuremedicine.com)

• Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics | Antimicrobial Agents and Chemotherapy (asm.org)

• Recommendations for travelling with bronchiectasis: a joint ELF/EMBARC/ERN-Lung collaboration | European Respiratory Society (ersjournals.com)

Year Six (2020-2021)

• Anti-biofilm activity of murepavadin against cystic fibrosis Pseudomonas aeruginosa isolates
• Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations
• Diagnosis and quantification of bronchiectasis using computed tomography or magnetic resonance imaging: A systematic review
• Evaluation of Rapid Polymyxin Pseudomonas test in clinical Pseudomonas aeruginosa isolates with various degrees of multidrug resistance
• Shopping for phages? Unpacking design rules for therapeutic phage cocktails
• Validation of the Bronchiectasis Impact Measure (BIM): a novel patient-reported outcome measure

• Inhaled corticosteroids use in patients with bronchiectasis: Data from the EMBARC registry | European Respiratory Society (ersjournals.com)

• Long term clinical outcomes of bronchiectasis in India: Data from the EMBARC/RRNI Indian Bronchiectasis Registry | European Respiratory Society (ersjournals.com)

• Deteriorating heath status in bronchiectasis : longitudinal data from the EMBARC registry | European Respiratory Society (ersjournals.com)

• Quality of care in bronchiectasis using the European Respiratory Society Guidelines as a reference standard- data from the EMBARC registry | European Respiratory Society (ersjournals.com)

• Determinants of survival in the European Bronchiectasis Registry(EMBARC) | European Respiratory Society (ersjournals.com)

• Characterization of clinical Ralstonia strains and their taxonomic position | Antonie van Leeuwenhoek (springer.com)

• Murepavadin antimicrobial activity against and resistance development in cystic fibrosis Pseudomonas aeruginosa isolates | Journal of Antimicrobial Chemotherapy | Oxford Academic (oup.com)

• Microorganisms | Free Full-Text | Presence of Chromosomal crpP-like Genes Is Not Always Associated with Ciprofloxacin Resistance in Pseudomonas aeruginosa Clinical Isolates Recovered in ICU Patients from Portugal and Spain (mdpi.com)

• The Neutrophil Granule Protein Olfactomedin-4 Relates to Bronchiectasis Severity and Alters Mucociliary Clearance

• Airway clearance techniques in patients with bronchiectasis. Data from the EMBARC Registry | European Respiratory Society (ersjournals.com)

• Frontiers | Multi-Omics Approaches: The Key to Improving Respiratory Health in People With Cystic Fibrosis? (frontiersin.org)

Year Seven (2022-2023)

• Biologically Relevant Murine Models of Chronic Pseudomonas aeruginosa Respiratory Infection
• Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)
• Clinical outcomes of bronchiectasis in India: data from the EMBARC/Respiratory Research Network of India registry
• Microbial Community Composition in Explanted Cystic Fibrosis and Control Donor Lungs
• Psychometric Validation of the German Translation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B)—Data from the German Bronchiectasis Registry PROGNOSIS 
• Taxonomic position, antibiotic resistance and virulence factors of clinical Achromobacter isolates
• Whole-genome analysis of Pandoraea species strains from cystic fibrosis patients

• WS13.02 Comparison of qPCR and 16S rRNA marker-gene Next-Generation Sequencing (NGS) for the detection and quantification of respiratory pathogens in the sputum of people with cystic fibrosis (PwCF) - Journal of Cystic Fibrosis (cysticfibrosisjournal.com)

• Taxonomic position, antibiotic resistance and virulence factor production by Stenotrophomonas isolates from patients with cystic fibrosis and other chronic respiratory infections | BMC Microbiology (springer.com)

• Establishing Antimicrobial Susceptibility Testing Methods and Clinical Breakpoints for Inhaled Antibiotic Therapy | Open Forum Infectious Diseases | Oxford Academic (oup.com)

• Transforming clinical research and science in bronchiectasis: EMBARC3, a European Respiratory Society Clinical Research Collaboration | European Respiratory Society (ersjournals.com)

• Multiple-Breath Washout Outcome Measures in Adults with Bronchiectasis | Annals of the American Thoracic Society (atsjournals.org)

ALX-009 Respiratory Infections

EMBARC Registry

iABC Ethical Advisory Board Harry Heijerman

iABC Overview

iABC Work Package 2 Marcel Hoppentocht

iABC Work Package 2 Maria Diez Aguilar

iABC Work Package 2 Miquel Ekkelenkamp

iABC Work Package 6 Michael Tunney

Inhaled TIP iBest Study Overview

Murepavadin

Clinical development of QBW251 for use in patients with bronchiectasis

Oral Presentations

Gisli G Einarsson (oral presentation)

Effect of treatment with the TOBI Podhaler® on the airway microbiota in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study

4th World Bronchiectasis & NTM Conference 2020

https://www.world-bronchiectasis-conference.org/2020/index.html

Zichuan Li (oral presentation)

Impact of ciprofloxacin treatment on Pseudomonas aeruginosa phenotypes in vitro

5th World Bronchiectasis & NTM Conference 2022

https://www.world-bronchiectasis-conference.org/2022/index.html

Michael Tunney (oral presentation)

qPCR and 16S rRNA marker-gene sequencing as endpoints for clinical trials of antimicrobials: iBEST study

European Respiratory Society Congress 2023

https://www.ersnet.org/congress-and-events/congress/programme/

Michael Tunney (oral presentation)

Effect of treatment with tobramycin on the airway microbiota and resistome in bronchiectasis patients chronically colonised with Pseudomonas aeruginosa: iBEST study

European Respiratory Society Congress 2023

https://www.ersnet.org/congress-and-events/congress/programme/

ePosters

ePoster Presentation: Laura Sherrard (oral presenter)

EPS9.04 Changes in biofilm-tolerance of Pseudomonas aeruginosa to tobramycin following treatment with tobramycin inhalation powder (TIP)

European Cystic Fibrosis Society Conference 2023

https://www.cysticfibrosisjournal.com/article/S1569-1993(23)00370-3/fulltext

ePoster Presentation: Deirdre Gilpin (oral presenter)

ePS3.08 Inhaled powder tobramycin (TIP): cyclical versus continuous treatment: iBEST Study

European Cystic Fibrosis Society Conference 2022

https://www.sciencedirect.com/science/article/pii/S156919932200306X?via%3Dihub

ePoster Presentation: Ross McCleave (oral presenter)

Phenotypic characterisation of Pseudomonas aeruginosa isolates from people with bronchiectasis following experimental evolution of tobramycin resistance

5th World Bronchiectasis & NTM Conference 2022

https://www.world-bronchiectasis-conference.org/2022/index.html

Posters

Inhaled Powder Tobramycin (TIP): Cyclical versus Continuous Treatment: iBEST Study

European Cystic Fibrosis Society Conference 2022

https://scholar.google.com/scholar?oi=bibs&cluster=16482572570696184737&btnI=1&hl=en

P126 Pseudomonas aeruginosa infection during long-term suppression treatment with tobramycin inhalation powder (TIP)

European Cystic Fibrosis Society Conference 2022

https://www.sciencedirect.com/science/article/pii/S1569199322004581?via%3Dihub

P147 Changes in Pseudomonas aeruginosa phenotypes following the development of tobramycin resistance

European Cystic Fibrosis Society Conference 2022

https://www.sciencedirect.com/science/article/pii/S1569199321011735?via%3Dihub

Changes in planktonic tolerance of Pseudomonas aeruginosa to tobramycin following treatment with tobramycin inhalation powder (TIP).

Microbiology Society Conference 2023.

https://microbiologysociety.org/event/annual-conference/annual-conference-2023.html

Poster Presentations

Chest physiotherapy in European Patients with Bronchiectasis: Data from the EMBARC Registry

Self-reported Asthma as a Co-morbidity of Bronchiectasis in the EMBARC registry

Participant Identification Centres (PICS)

Content Validation of the Respiratory Symptoms Subscale (RSS) of the Quality of Life Questionnaire-Bronchiectasis (QoL-B) in Non-Cystic Fibrosis Bronchiectasis (NON-CF BE)

Multiple Breath Washout (MBW) training, certification and quality control during the iBEST-1 trial in bronchiectasis (BE)

Dose-finding study to assess the efficacy, safety and tolerability of tobramycin inhalation powder in patients with non-cystic fibrosis bronchiectasis and pulmonary Pseudomonas aeruginosa infection (iBEST-1)